Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2016

View Archived Issues

Researchers investigate Nampt inhibitors without CYP2C9 inhibitory effects

PTC Therapeutics presents antibacterial compounds

First-in-human phase I results for the tuberculosis vaccine MVA85A-IMX313

Shire discloses dopamine transporter inhibitors

Shanghai Institute of Organic Chemistry patents indoleamine dioxygenase inhibitors

Proximagen Group presents amine oxidase inhibitors

SIMM, Suzhou Vigonvita Life Sciences and Topharman Shanghai develop antiepileptic compounds

Novartis divulges c-Raf inhibitors

Janssen files application for ibrutinib in Japan

Gilead Sciences acquires Nimbus Therapeutics' ACC inhibitor program

Single-dose and preservative-free formulation of Makena launched in the U.S.

Topical formulation of pritelivir enters phase I clinical testing

Portola and Daiichi Sankyo to develop andexanet alfa with edoxaban in Japan

Second phase II study of NP-001 will enroll patients using biomarker for enriched selection

Boehringer Ingelheim and Kyoto University to investigate new drugs for sensorineural hearing loss

Nerviano Medical Sciences licenses drug-linker technology to Oxford Biotherapeutics

Intrexon creates joint venture to develop treatment for type 1 diabetes

Intec Pharma enrolls first patient in pivotal phase III Parkinson's trial

Multiple sclerosis vaccine well tolerated in phase II study

MJFF awards grant to VCU for Parkinson's disease drug trial

Portable electronic nose shows promise for cancer diagnosis

FDA approves Gilead's Descovy for the treatment of HIV

Silence Therapeutics presents data from Atu-027-I-02 clinical trial

JAK2 shows promise as a prognostic biomarker in NPC

Acucela and UoM announce agreement for the development of an optogenetic gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...